HIV-1 Drug Resistance Testing: Health Outcomes Issues

Bozzette S.A. , Berry S.H. , Duan N. , Frankel M.R. , Leibowitz A.A. , Lefkowitz D. , Emmons C.A. , Senterfitt J.W. , Berk M.L. , & Morton S.C. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. New England Journal of Medicine 1998; 339: 1897–1904.

Perdue B.E. , Weidle P.J. , Everson-Mays R.E. , & Bozek P.S. Evaluating the cost of medications for ambulatory HIV-infected persons in association with landmark changes in antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998; 17: 354–360.

Lapins D. , Barrett J. , Hamel E. , Urdaneta M. , & Markson L.E. Trends in Costs of Care for Patients with HIV. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA, 1998. Abstract 460.

Lacey L. , Youle M. , Trueman P. , Staszewski S. , Shrappe M. , & Behrens M. A prospective evaluation of the cost of adding lamivudine to zidovudine containing antiretroviral treatment regimens in HIV infection. Pharmacoeconomics 1999; 15(Suppl. 1):39–53.

Stansell J. , Barrett J. , Holtzer C. , & Lapins D. Incremental costs of HIV suppression in HIV therapeutic failure. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, 2000. Abstract 761.

Durant J. , Clevenburgh P. , Halfon P. , Delgiudice P. , Porsin S. , Simonet P. , Montagne N. , Boucher C.A. , Schapiro J.M. , & Dellamonica P. Drug resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195–2199.

Chaix C. , Grenier-Sennelier C. , Durant J. , Clevenberg P. , Shapiro J.M. , Dellamonica P.m. , & Durand-Zaleski I. Economic Evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study. 3rd International Workshop on HIV Drug Resistance and Treatment Strategies, San Diego, USA, 1999. Abstract 105.

Anis A.H. , Wang X. , Harrigan R. , Hogg R.S. , Yin B. , O'Shaughnessy M.V. , Schlechter M.T. , & Montaner J.S.G. The cost-effectiveness of immediate ritonavir-saquinavir therapy versus resistance testing and a drug holiday in HIV patients failing protease inclusive regimens. Society for Medical Decision Making, Reno, USA, 1999. Abstract 88.

Anis A.H. , Wang X. , Harrigan R. , Hogg R.S. , Yin B. , O'Shaghnessy M.V. , Schlechter M.T. , & Montaner J.S.G. Optimizing drug treatment: a cost-effectiveness analysis of HIV/AIDS drug resistance testing. Society for Medical Decision Making, Reno, USA, 1999. Abstract 29.

Weinstein M.C. , Goldie S.J. , Cohen C. , Losina H. , Zhang H.J. , Kimmel A.D. , & Freedberg K.A. Resistance testing to guide the choice of second-line antiretroviral therapy in HIV: clinical impact and cost-effectiveness. Society for Medical Decision Making, Reno, USA 1999. Abstract 68.

Simpson K.N. Value and budget impacts integrating anti-retroviral genotypic resistance testing into HIV treatment guidelines. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA 1999. Abstract 789.

Dreezen C. , Barrata C. , Coppieters Y. , Caldeira L. , Liotta G. , & Colebunders R. Utilization of health services for HIV+ patients in Europe. 7th European Conference on Clinical Aspects of Treatment of HIV Infection, Lisbon, Portugal, 1999. Abstract 240.

Klein D.B. , & Hurley L. HAART-related cost saving from decreased utilization of diagnostic microbiology lab. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, 1999. Abstract 465.

Lundgren J. , Katlama C. , Johnson A. , Pradier C. , Antunes F. , Mulcahy F. The changing spectrum of AIDS across Europe 1994–1999. The Eurosida Study. 7th European Conference on Clinical Aspects of Treatment of HIV Infection, Lisbon, Portugal, 1999. Abstract 244.

Goldie S.J. , Kaplan J.E. , Losina H. , Weinstein M.C. , Paltiel A.D. , Seage G.R. , Craven D.E. , Kimmel A.D. , Zhang H.J. , Cohen C.J. , & Freedberg K.A. Resistance testing to guide the choice of second-line antiretroviral therapy in HIV: clinical impact and cost-effectiveness. Society for Medical Decision Making, Reno, USA, 1999. Abstract 86.